Niosomal hesperidin ameliorates depression-induced behavioral, histological, and molecular alterations in the rat hippocampus

Niosomal carriers offer a promising drug delivery in neurological disorders. This study evaluated the therapeutic effects of niosome-encapsulated hesperidin on reserpine-induced depression in rats, focusing on oxidative stress, transient receptor potential melastatin2 (TRPM2) and transient receptor...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Biomedicine & pharmacotherapy Ročník 191; s. 118473
Hlavní autoři: Otarkhani, Mahsa, Hatami, Homeira, panahi, Yousef, Jammal, Abdallah Al, Sadeghian, Reihaneh, Yavari, Sama
Médium: Journal Article
Jazyk:angličtina
Vydáno: France Elsevier Masson SAS 01.10.2025
Témata:
Animals
Antidepressive Agents - administration & dosage
Antidepressive Agents - pharmacology
Behavior, Animal - drug effects
Depression
Depression - chemically induced
Depression - drug therapy
Depression - metabolism
Depression - pathology
Disease Models, Animal
Hesperidin - administration & dosage
Hesperidin - pharmacology
Hippocampus - drug effects
Hippocampus - metabolism
Hippocampus - pathology
Internal Medicine
Liposomes
Male
Nanoparticle
Niosome-hesperidin
Oxidative Stress - drug effects
Rats
Rats, Wistar
Reserpine
TRPC Cation Channels - genetics
TRPC Cation Channels - metabolism
TRPM Cation Channels - genetics
TRPM Cation Channels - metabolism
TRPM2
TRPMC1
Niosome-hesperidin
TRPM2
Depression
TRPMC1
Nanoparticle
ISSN:0753-3322, 1950-6007, 1950-6007
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Niosomal carriers offer a promising drug delivery in neurological disorders. This study evaluated the therapeutic effects of niosome-encapsulated hesperidin on reserpine-induced depression in rats, focusing on oxidative stress, transient receptor potential melastatin2 (TRPM2) and transient receptor potential canonical 1(TRPC1) gene expression levels, and histo-striology changes in hippocampal tissue. 36 rats were randomly divided into six groups, including Control, Depression, Hes (Hesperidin), nHes (Niosomes of Hesperidin), Dep+Hes, and Dep+nHes. Reserpine 0.5 mg/kg was administered intraperitoneally to induce the Dep Model for 14 days. Then, with intraperitoneal injection, rats received Hes (20 mg/kg for 14 days) and nHes (20 mg/kg for 7 days). Next, the Forced Swimming Test (FST) and the Sucrose Preference Test (SPT) were applied to assess Behavioral disorders. Finally, Glutathione peroxidase (GPX) levels, malondialdehyde (MDA), TRPM2, and TRPC1 gene expression, as well as histo-stereological studies, were measured in hippocampal tissue. The nHSP treatment reduced immobility duration and increased sucrose solution consumption compared to the depression group in behavioral tests. The expression of genes TRPM2 decreased in the Dep+nHSP group compared with the depression group, and TRPC1 decreased in the HSP group compared with the depression group. Histological and stereological studies revealed improved apoptosis and cell death in nHSP-treated rats, with an increase in live cells compared to the depressed group. Our findings suggest that nHes improves depression phenotypes induced by reserpine by reducing hippocampal oxidative stress damage and histopathological alterations. This may be related to enhanced therapeutic efficacy and bioavailability due to liposomal carriers. [Display omitted] •Hesperidin-loaded niosomes reduced depressive-like behaviors in rats.•TRPM2 and TRPC1 gene expression were significantly reduced.•GPx antioxidant activity was increased after treatment with hesperidin niosomes.•MDA levels and neuronal apoptosis were significantly reduced.•Hesperidin niosomes showed faster and more effective action than hesperidin.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0753-3322
1950-6007
1950-6007
DOI:10.1016/j.biopha.2025.118473